---
document_datetime: 2024-09-11 10:20:54
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tadalafil-lilly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tadalafil-lilly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1260556
conversion_datetime: 2025-12-25 04:26:46.886725
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tadalafil Lilly

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/2697              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing | 05/09/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | authorisation, including the RMP - Other variation                                                                                                                                                                                           |            |            |                                  |                                                                                                                                                                                                                                                                               |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2841/ 202210 | Periodic Safety Update EU Single assessment - tadalafil                                                                                                                                                                                      | 22/06/2023 | 23/08/2023 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2841/202210.                                                                                                                                     |
| IG/1620            | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                               | 01/08/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                               |
| R/0008             | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 16/09/2021 | 12/11/2021 | SmPC, Labelling and PL           | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Tadalafil Lilly in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| N/0007             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 05/03/2021 | 12/11/2021 | Labelling                        |                                                                                                                                                                                                                                                                               |
| WS/1940            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 28/01/2021 | 12/11/2021 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                               |
| PSUSA/2841/ 201910 | Periodic Safety Update EU Single assessment - tadalafil                                                                                                                                                                                      | 11/06/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                             |
| IG/1133            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch                                                                                               | 14/08/2019 | n/a        |                                  |                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | control/testing takes place                                                                                                                                                                                                                                                                                                                     |            |            |                        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IG/0914   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                      | 15/03/2018 | n/a        |                        |
| IB/0002   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                   | 09/01/2018 | n/a        |                        |
| IB/0001/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 12/06/2017 | 31/05/2018 | SmPC, Labelling and PL |